NCT02322814 2023-04-13A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has SpreadHoffmann-La RochePhase 2 Terminated169 enrolled 31 charts
NCT03566485 2021-08-11Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerVanderbilt-Ingram Cancer CenterPhase 1/2 Terminated12 enrolled 13 charts
NCT01813214 2019-02-26The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With MelanomaGeorgetown UniversityPhase 2 Terminated5 enrolled 7 charts
NCT01495988 2017-10-24Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaMelanoma Research Foundation Breakthrough ConsortiumPhase 2 Terminated10 enrolled 10 charts